Buyout Bid Overshadows NxStage Medical's Losses
Dialysis patients know how inconvenient it can be to make time for their treatments, and NxStage Medical (NASDAQ: NXTM) has sought to make dialysis much less of a burden through its home dialysis equipment. Even though some investors had recently started to worry about the prospects for fast growth from the company, NxStage got a huge vote of confidence from Fresenius Medical Care (NYSE: FMS), and the resulting celebration among investors is overshadowing NxStage's actual financial results.
Coming into Monday's second-quarter financial report, NxStage investors had no inkling that a merger would be right around the corner, and they had mixed expectations about how much growth the medical device maker would be able to produce. NxStage's numbers were a bit disappointing, but all that is likely to pale in comparison to the importance of the proposed acquisition. Let's look more closely at NxStage Medical and what happened today.
Image source: NxStage Medical.
Source: Fool.com
Fresenius Medical Care AG & Co KGaA ADR Aktie
Positive Stimmung für Fresenius Medical Care AG & Co KGaA ADR mit mehreren Buy- gegenüber Sell-Einschätzungen.
Für Fresenius Medical Care AG & Co KGaA ADR ergibt sich ein leicht positives Potenzial, angesichts eines Kursziels von 21 € im Vergleich zu 19.4 €.
